The landscape of patent reviews related to biologics has witnessed notable trends since the establishment of the Patent Trial and Appeal Board (PTAB) in 2012. By the end of 2025, a total of 330 inter partes review (IPR) petitions and 43 post-grant review (PGR) petitions concerning biologics were filed. This reflects the significant role that biologics continue to play in patent litigation.
One prominent trend is the rise in patent challenges as more biologic drugs come off patent, prompting pharmaceutical companies to defend their intellectual property vigorously. The PTAB has become a vital arena for these disputes, providing a forum for companies to contest patent claims that could impede market competition and innovation. As detailed by some legal experts, this trend underscores the shifting dynamics within the pharmaceutical industry, as companies leverage IPRs and PGRs as strategic tools.
The biologics sector, with its complex biotechnological processes, often crosses paths with the regulatory landscape, creating unique challenges. The U.S. Food and Drug Administration’s (FDA) approval process for biosimilars adds another layer to this complexity. Many petitions filed at the PTAB are aimed at navigating these intricate landscapes to either pave the way for new biosimilars or maintain exclusivity on existing biologics. This trend is expected to continue as the market for biosimilars expands and more biologics reach the end of their patent life spans.
Moreover, recent amendments to patent laws and policies aimed at streamlining IPR processes have also impacted biologics-related cases. The development of these legal frameworks ensures that both innovators and biosimilar manufacturers have a clear path to contest or defend patent claims. As reported by legal analysts, the evolving patent landscape requires stakeholders to stay informed to maintain competitive advantages.
For legal professionals navigating this intricate domain, a comprehensive understanding of biologics-related patent review trends is crucial. Staying informed about the dynamics at play can provide strategic advantages in patent litigation cases. More detailed insights and developments in this field can be found through specialized legal analyses and platforms offering real-time updates, such as Law360.